Serum Asprosin, Metabolic Syndrome, and Cardiometabolic Risk in Rheumatoid Arthritis

NCT07793747 | Not Yet Recruiting

• 1 other identifier: Asprosin in RA & MetS Risk
• Study Type: observational
• Target: 75
• Locations: 0 countries
• Sites: N/A

Brief Summary

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease associated with a significantly increased risk of cardiovascular disease and metabolic syndrome (MetS). Asprosin is a recently identified adipokine involved in glucose regulation, insulin resistance, and systemic inflammation, but its role in the cardiometabolic complications of RA remains incompletely understood. The purpose of this case-control study is to evaluate and compare serum Asprosin levels among RA patients with metabolic syndrome, RA patients without metabolic syndrome, and healthy control individuals. The study will also assess the association between serum Asprosin concentrations, RA disease activity (DAS28-ESR), and various cardiometabolic risk indices (including TyG index, Atherogenic Index of Plasma, and Castelli risk indices). Participants will undergo a comprehensive clinical assessment, disease activity scoring, physical function evaluation using the Health Assessment Questionnaire (HAQ), and laboratory investigations including fasting blood tests and serum Asprosin measurement via ELISA. Findings from this study may help clarify the pathophysiological role of Asprosin in RA and improve cardiometabolic risk stratification in affected patients.

Conditions

Rheumatoid Arthritis; Metabolic Syndrome; Cardiovascular Diseases

Keywords

Asprosin; Cardiometabolic Risk; DAS28; Adipokines; Atherogenic Index of Plasma; Triglyceride-Glucose Index; Insulin Resistance

Outcome Measures

Primary Outcomes (1)

• Serum Asprosin Level

  Serum asprosin concentration (measured in ng/mL) assessed via a commercial enzyme-linked immunosorbent assay (ELISA) kit to compare rheumatoid arthritis patients with metabolic syndrome versus rheumatoid arthritis patients without metabolic syndrome.

  Baseline

Study Arms (3)

Rheumatoid Arthritis with Metabolic Syndrome

Adult patients diagnosed with rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria who also meet the NCEP ATP III criteria for metabolic syndrome (presence of 3 or more metabolic components). Serum Asprosin levels and cardiometabolic risk indices will be evaluated.

Rheumatoid Arthritis without Metabolic Syndrome

Adult patients diagnosed with rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria who do not meet the NCEP ATP III diagnostic criteria for metabolic syndrome. Serum Asprosin levels and cardiometabolic risk indices will be evaluated.

Healthy Controls

Age- and sex-matched healthy control individuals without rheumatoid arthritis, metabolic syndrome, or systemic inflammatory conditions, recruited for comparative assessment of baseline serum Asprosin levels.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients aged 18 years and older diagnosed with rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria, recruited from the inpatient and outpatient clinics of the Rheumatology, Rehabilitation, and Physical Medicine Department at Assiut University Hospital, along with age- and sex-matched healthy control individuals.

You may qualify if:

• Adult patients aged 18 years or older.
• Diagnosis of rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria.
• Ability and willingness to provide written informed consent.
• Healthy controls: Age- and sex-matched individuals without rheumatoid arthritis or systemic inflammatory diseases.

You may not qualify if:

• Presence of other autoimmune diseases or overlap syndromes.
• Active acute or chronic infectious diseases.
• Pregnancy or lactation.
• Current malignancy or previous history of malignancy.
• Severe hepatic or renal impairment.
• Receipt of medications primarily prescribed for weight reduction or agents known to markedly alter lipid or glucose metabolism, other than standard rheumatoid arthritis therapy.

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Arthritis, Rheumatoid; Metabolic Syndrome; Cardiovascular Diseases; Arachnodactyly; Insulin Resistance

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Limb Deformities, Congenital; Musculoskeletal Abnormalities; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident of Rheumatology, Rehabilitation and Physical medicine

Study Record Dates

• First Submitted: August 26, 2026
• First Posted: August 31, 2026
• Study Start: October 1, 2026
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): November 1, 2027
• Last Updated: August 31, 2026

Record last verified: 2026-08